We used metabolic control analysis to determine the flux control coefficient of phosphorylase on glycogen synthesis in hepatocytes by titration with a specific phosphorylase inhibitor (CP-91149) or by expression of muscle phosphorylase using recombinant adenovirus. The muscle isoform was used because it is catalytically active in the b-state. CP-91149 inactivated phosphorylase with sequential activation of glycogen synthase. It increased glycogen synthesis by 7-fold at 5 mM glucose and by 2-fold at 20 mM glucose with a decrease in the concentration of glucose causing half-maximal rate (S 0.5 ) from 26 to 19 mM. Muscle phosphorylase was expressed in hepatocytes mainly in the b-state. Low levels of phosphorylase expression inhibited glycogen synthesis by 50%, with little further inhibition at higher enzyme expression, and caused inactivation of glycogen synthase that was reversed by CP-91149. At endogenous activity, phosphorylase has a very high (greater than unity) negative control coefficient on glycogen synthesis, regardless of whether it is determined by enzyme inactivation or overexpression. This high control is attenuated by glucokinase overexpression, indicating dependence on other enzymes with high control. The high control coefficient of phosphorylase on glycogen synthesis affirms that phosphorylase is a strong candidate target for controlling hyperglycemia in type 2 diabetes in both the absorptive and postabsorptive states.
The liver maintains blood glucose homeostasis by uptake of glucose in the absorptive state, which is converted to glycogen and triacylglycerol, and by production of glucose from glycogenolysis and gluconeogenesis in the postabsorptive state. Glycogen phosphorylase catalyzes the first step in glycogen degradation (1) . It is regulated by allosteric mechanisms and by phosphorylation of Ser-14 by phosphorylase kinase. The dephosphorylated form (phosphorylase b) is less active than the phosphorylated form (phosphorylase a) (1) . Hormones that raise cAMP or cytoplasmic Ca 2ϩ favor the formation of phosphorylase a, whereas insulin and leptin have the converse effect (1, 2) . Phosphorylase is a dimer and exists in two conformations, an inactive T-state (tight) and an active R-state (relaxed). The R-state is favored by substrate, phosphorylation, and allosteric activators (AMP), whereas the T-state is favored by dephosphorylation and by inhibitors (glucose, glucose 6-P, 1 and caffeine) (3, 4) . The liver isoform, unlike the muscle isoform, is more tightly controlled by phosphorylation than by allosteric regulation (1) .
Two sets of evidence suggest that liver phosphorylase is a candidate pharmacological target for controlling hyperglycemia in diabetes. Firstly, a potent inhibitor of liver phosphorylase a that acts synergistically with glucose lowers blood glucose in the leptin-deficient ob/ob mouse (5) . Secondly, the activity of phosphorylase is elevated in the leptin receptor-defective db/db mouse (6) and Zucker fa/fa rat (7) , which are widely used as animal models for human type 2 diabetes and insulin resistance.
Recent studies have applied metabolic control analysis (8) to determine how control of glycogen synthesis is shared between diverse sites. In skeletal muscle, a high degree of control resides at the glucose transport/phosphorylation sites (9 -11), whereas in liver, a high degree of control is exerted by glucokinase in conjunction with its regulatory protein (12) (13) (14) . Schulz (11) developed a minimal model for glycogen synthesis in muscle that demonstrates that as glycogenolysis increases, the distribution of control shifts to the terminal enzymes in the glycogen synthesis pathway. Mathematical models enable identification of conditions that alter the distribution of control but do not allow a quantitative estimate of the degree of control exerted by specific sites. There has been no experimental analysis of the control exerted by phosphorylase on glycogen synthesis. In this study, we used a specific inhibitor of phosphorylase (5) and titrated phosphorylase overexpression by adenovirus-mediated gene transfer of the muscle isoform of phosphorylase (15) to determine the flux control coefficient of phosphorylase on glycogen synthesis in hepatocytes. Muscle phosphorylase b, unlike liver phosphorylase b (16) , is very sensitive to activation by AMP. We took advantage of this property of muscle phosphorylase to increase phosphorylase catalytic activity in hepatocytes independently of the phosphorylation state of the hepatocyte.
hepatocytes were suspended in minimal essential medium containing 7% newborn calf serum and seeded in multiwell plates (12) . After cell attachment (2-3 h), they were incubated for 2 h in serum-free minimal essential medium containing recombinant adenovirus encoding either muscle glycogen phosphorylase (AdCMV-MGP (15)) or liver glucokinase (AdCMV-GK (17)). The medium was then replaced by minimal essential medium containing 10 nM dexamethasone and 5 mM glucose, and the cells were cultured for 16 -18 h (12) .
Metabolic Studies-For determination of glycogen synthesis, hepatocytes were incubated in minimal essential medium containing [U-
14 C]glucose (2 Ci/ml) and the glucose concentrations indicated without or with insulin (10 nM) for 3 h. Parallel incubations without radiolabel were performed for enzyme activity or metabolite determination. Incorporation of 14 C label into glycogen was determined by ethanol precipitation (18) , and rates of glycogen synthesis are expressed as nmol glucose incorporated/3 h per mg cell protein. The glucose concentration that causes a half-maximal rate was determined from Hill plots, using Fig.P -Biosoft Software. Glycogen was determined analytically using amyloglucosidase (18) and is expressed as nmol glucosyl residues/mg protein. Glucose 6-P, ATP, and protein were determined as described previously (19) . Glycolysis was determined from detritiation of H]glucose (19) and incorporation of [U- 14 C]glucose into triacylglycerol as described in Ref. 20 .
Enzyme Activity Determination-For determination of glycogen synthase and phosphorylase, hepatocyte monolayers were extracted as described previously (7) . Active glycogen synthase and total glycogen synthase were determined in the absence or presence of glucose 6-P, respectively (21) . Active synthase is expressed as m-units/mg cell protein or as the activity ratio (Ϫglucose 6-P/ϩ glucose P). Phosphorylase was assayed spectrometrically in the glycogenolytic direction from the phosphate-induced hydrolysis of glycogen coupled to phosphoglucomutase and glucose 6-P dehydrogenase (2, 7). Phosphorylase a was assayed as described in Ref. 2 . Total liver or total muscle phosphorylase was assayed as described in Ref. 7 by converting phosphorylase b to phosphorylase a with phosphorylase kinase (22) . Total muscle phosphorylase was also assayed in the presence of 5 mM AMP under assay conditions that were otherwise similar to those used for assay of phosphorylase a. To determine the catalytic activity of the muscle isoform under physiological conditions, an assay designated "active phosphorylase assay" was used. This assay was based on the phosphorylase a assay, except that 10 mM glucose, 0.2 mM AMP, and 2 mM ATP were substituted for caffeine. Other assays were modifications of the active phosphorylase assay, using different concentrations of AMP and ATP. Enzyme activities are expressed as m-units/mg cell protein, where 1 m-unit converts 1 nmol substrate/min. Glucokinase activity (free and bound fractions) was determined as described in Ref. 12 .
Determination of Control Coefficients-The control coefficient (C e J ) of an enzyme (e) on pathway flux (J) is defined as the fractional change in metabolic flux (␦J/J) resulting from a fractional change in enzyme activity (␦e/e) (8) . It was determined from the initial slope of double logarithmic plots of flux (J) against enzyme activity (e) for titrations of CP-91149 or enzyme expression with Ad-CMV-MGP (23) .
The control coefficient of phosphorylase on glycogen synthase activity was determined from the slope of ln active glycogen synthase against ln phosphorylase activity. All results are expressed as the means Ϯ S.E. for the number of cell preparations indicated. Statistical analysis was performed using Student's paired t test.
RESULTS

CP-91149 Causes Inactivation of Phosphorylase and Sequential Activation of Synthase and Increases the Affinity of Glycogen Synthesis for
Glucose-We used a potent inhibitor of liver phosphorylase a, [R-(R,S)-5-chloro-N-[3-(dimethylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide (CP-91149) (5) , to determine the relation between phosphorylase activity and glycogen synthesis. Incubation of hepatocytes with 2.5 M CP-91149 caused inactivation of phosphorylase a (Fig. 1A) and activation of glycogen synthase in the absence of glucose 6-P (Fig. 1B) . The former (but not the latter) was significant after 5 min, indicating that activation of synthase is delayed relative to inactivation of phosphorylase. There was no change in the total activity of glycogen synthase assayed in the presence of glucose 6-P; accordingly, changes in the active form of synthase (Fig. 1B) were associated with similar changes in the activity ratio (data not shown). When the cells were preincubated with 2.5 M CP-91149 for 1 h and then incubated in medium without inhibitor for 3 h, the recovery of phosphorylase activity relative to that in untreated controls was 20% (data not shown), indicating that reactivation of phosphorylase is slow after removal of inhibitor. Fig. 2 shows the activity of phosphorylase and the rate of glycogen synthesis in relation to varying glucose concentration in the absence or presence of 2.5 M CP-91149. Glucose caused a concentration-dependent inactivation of phosphorylase, and the inactivation by CP-91149 was additive with the effect of glucose ( Fig. 2A) . The rate of glycogen synthesis was a sigmoidal function with respect to glucose concentration (Fig. 2B) , with a half-maximal rate obtained at a concentration of glucose (S 0.5 ) of 25.6 Ϯ 1.1 mM and a Hill coefficient (h) of 2.8 in the absence of inhibitor (Fig. 2B) . CP-91149 (2.5 M) caused a 7-fold increase in glycogen synthesis at 5 mM glucose and a 2-fold increase at 20 -25 mM glucose with a leftward shift of the glucose saturation curve and a decrease (p Ͻ 0.03) in S 0.5 for glucose to 18.9 Ϯ 2.1 mM (h 2.2).
The Flux Control Coefficient of Phosphorylase on Glycogen Synthesis Determined by Inhibitor Titration-The flux control coefficient (C e J ) of an enzyme (e) on pathway flux (J) is a measure of the fractional change in flux that results from a fractional change in enzyme activity (8) and can be determined from the initial slope of a double logarithmic plot of flux against enzyme activity (23) . To determine the flux control coefficient of phosphorylase on glycogen synthesis, hepatocytes were incubated with varying concentrations of CP-91149 for parallel determination of phosphorylase activity and glycogen synthesis ( Fig. 3, A and B) . The flux control coefficient determined from the initial slope of the double logarithmic plot was Ϫ1.6 Ϯ 0.16 (means Ϯ S.E.; n ϭ 4).
Muscle Phosphorylase Is Expressed in Hepatocytes in the b Form but Is Activated by Glucagon-To determine the control coefficient of phosphorylase by enzyme overexpression, we expressed muscle phosphorylase in hepatocytes using recombinant adenovirus. We used the muscle isoform because it is active at physiological concentrations of AMP and ATP, unlike the liver isoform. The activity of phosphorylase a in control hepatocytes was 10% of total activity and was increased 2.6-fold by glucagon (Table I) . Hepatocytes treated with a titer of AdCMV-MGP (50 l/ml) that resulted in a 70% increase in total phosphorylase had a similar activity of phosphorylase a as untreated hepatocytes (Table I) . However, after incubation with glucagon, phosphorylase a activity was higher in AdCMV-MGP-treated cells than in untreated cells (29.3 versus 20.9 m-units/mg). This difference in activity is 17% of total muscle phosphorylase (50 m-units/mg) and is similar to the increase in phosphorylase a caused by glucagon in untreated hepatocytes, which is also 17% of total liver phosphorylase. This indicates that muscle phosphorylase in AdCMV-MGP-treated hepatocytes is expressed mainly in the b form, but it is activated by glucagon to the same extent as endogenous liver phosphorylase.
To account for the difference in sensitivity to AMP between liver and muscle isoforms, two additional assays were used designated the active phosphorylase assay and the AMP assay. The former has physiological concentrations of AMP (0.2 mM), ATP (2 mM), and glucose (10 mM) to simulate the concentrations of these allosteric effectors in hepatocytes, and the latter has a saturating (5 mM) concentration of AMP (Table I ). In untreated hepatocytes (which express only liver phosphorylase), the activity assayed with 5 mM AMP was 18% of total activity (Table I ). The difference in activity between untreated and AdCMV-MGP-treated cells in the presence of 5 mM AMP (13-66 m-units/mg) was equal to the difference in total phosphorylase (75-125 m-units/mg). This confirms that 5 mM AMP fully activates the b isoform of muscle but not the b isoform of liver. The active phosphorylase assay shows a similar activity as the phosphorylase a assay for the endogenous phosphorylase in untreated hepatocytes but shows a 2-fold higher activity in hepatocytes expressing muscle phosphorylase (Table I) . This confirms that muscle phosphorylase b but not liver phosphorylase b is catalytically active at physiological concentrations of AMP and ATP. from AdCMV-MGP-treated cells). It is noteworthy that at saturating concentrations of AMP (5 mM), the activity of the muscle isoform is equal to total muscle activity, whereas the activity of the endogenous enzyme is 18% of total liver phosphorylase. This is due to the low affinity of liver phosphorylase b for its substrate, inorganic phosphate, at saturating AMP concentrations (16) . Table II shows the effects of the four titers of AdCMV-MGP used in the rest of this study on the activity of phosphorylase as determined by the different assays. With titrated expression of the muscle isoform, there was negligible change in phosphorylase a. However, there was a progressive increase in activity by all the assays containing AMP. Control coefficients were determined using either the active phosphorylase assay or the AMP assay.
Expression of AdCMV-MGP Inhibits Glycogen Synthesis and Inactivates Glycogen Synthase-Expression of muscle phosphorylase in hepatocytes using the titers of AdCMV-MGP shown in Table II caused a sharp inhibition of glycogen synthesis at the lowest viral titer (5 l/ml), with little further inhibition at higher titers (Fig. 5A) . However, there was a progressive decrease in the active form of glycogen synthase with increasing phosphorylase overexpression (Fig. 5B) . The activity ratio of synthase (Ϫglucose 6-P/ϩ glucose P) decreased by 50% at the highest viral titers (control, 0.26 Ϯ 0.03; 50 l of AdCMV-MGP, 0.13 Ϯ 0.02; insulin, 0.35 Ϯ 0.02; 50 l of AdCMV-MGP ϩ insulin, 0.17 Ϯ 0.02 (means Ϯ S.E.); n ϭ 4). When the rate of glycogen synthesis was plotted against the active glycogen synthase, the relation was nonlinear (Fig. 5C ), indicating that progressive inactivation of glycogen synthase is not associated with further inhibition of glycogen synthesis. Insulin stimulated glycogen synthesis and activated glycogen synthase in both untreated and AdCMV-MGP-treated cells, indicating that phosphorylase expression does not override the effects of insulin.
The inactivation of synthase by treatment with AdCMV-MGP was not associated with changes in glucose 6-P (means Ϯ S.E. Table III . Flux control coefficients of phosphorylase on glycogen synthesis were about Ϫ2 and were similar regardless of whether they were determined by the active phosphorylase assay or by the AMP assay (Table III) . Similar coefficients were obtained from the initial slopes by the other AMP-containing assays shown in Table   TABLE I Phosphorylase a and total phosphorylase in hepatocytes treated with AdCMV-MGP Hepatocytes were either untreated or treated with 50 l/ml AdCMV-MGP and cultured for 16 h. Glucagon (100 nM) was added, where indicated, 5 min before the end of the incubations. Phosphorylase activity (m-units/mg) was determined by the four assays described under "Experimental Procedures." Muscle phosphorylase (MGP) activity was estimated by subtraction of endogenous activity in untreated hepatocytes from the activity in AdCMV-MGP-treated cells. Values represent the means Ϯ S.E. for four to nine cultures. II (data not shown). The control coefficients of phosphorylase on synthase activity were lower than those on glycogen synthesis by about 50% (Table III) .
Effects of Glucokinase Overexpression on the Control Coefficient of Phosphorylase-Glucokinase has a very high flux control coefficient on glycogen synthesis (12), which is counterbalanced in part by the negative control exerted by its regulatory protein (14) . To determine whether the control coefficient of phosphorylase on glycogen synthesis is dependent on glucokinase activity, we overexpressed glucokinase by 60% above endogenous activity (27 Ϯ 4 versus 17 Ϯ 3 m-units/mg protein). Glucokinase overexpression stimulated glycogen synthesis ( Fig. 6A ) and activated glycogen synthase (Fig. 6B) . Expression of muscle phosphorylase inhibited glycogen synthesis by 50% in controls expressing endogenous glucokinase and by 30% in cells overexpressing glucokinase (Fig. 6A ) and caused parallel inactivation of glycogen synthase (Fig. 6B) . Total glucokinase activity and distribution between free and bound states were not affected by phosphorylase overexpression (data not shown). Fig. 6C shows the relation between glycogen synthesis and active glycogen synthase. In the control incubations with 25 mM glucose, there was a nonlinear relation as observed with 10 mM glucose (Fig. 5C ). In cells overexpressing glucokinase, the response was shifted toward higher synthesis and synthase activity. The flux control coefficient of phosphorylase on glycogen synthesis (as determined from the initial slope of the double logarithmic plot of the data in Fig. 6A ) was significantly lower in cells overexpressing glucokinase (Table III) , whereas the control coefficient of phosphorylase on glycogen synthase (Fig. 6B ) was unchanged (Table III) .
CP-91149 Partially Counteracts the Effects of AdCMV-MGP-
To test whether the inhibition of glycogen synthesis and inactivation of glycogen synthase by treatment with AdCMV-MGP can be explained by the catalytic activity of muscle phosphorylase b as opposed to other mechanisms, we determined whether CP-91149 counteracts the effects of phosphorylase overexpression. CP-91149 is a potent inhibitor of human liver phosphorylase a (IC 50 ϭ 0.13 M (5)) and human muscle phosphorylase a (IC 50 ϭ 200 nM (24)). Fig. 7 shows that it is also a potent inhibitor of muscle phosphorylase b (IC 50 ϳ0.3 M) assayed in the presence of 10 mM glucose, 0.2 mM AMP, and 2 mM ATP. Table IV shows the combined effects of the inhibitor and phosphorylase overexpression. The inhibitor (10 M) caused a 2-fold increase in glycogen synthesis (p Ͻ 0.03) and cell glycogen content (p Ͻ 0.04) and 40% activation of glycogen synthase (p Ͻ 0.02) in the untreated controls expressing only endogenous phosphorylase, and it counteracted the suppression of glycogen synthesis and inactivation of glycogen synthase in cells treated with low titers of AdCMV-MGP. However, the inhibitor did not fully counteract the effects of high titers of AdCMV-MGP (Table IV) . Because the control coefficients in Table III were determined from the initial slope using the lowest titer of AdCMV-MGP, these values are most likely due to the catalytic activity of muscle phosphorylase.
DISCUSSION
Metabolic control analysis is a powerful analytical approach to describe how control of flux through a metabolic pathway is Table  II . Glycogen synthesis (expressed as nmol/3 h per mg) was determined from 3-h incubations with 10 mM [U- 14 C]glucose without (q and E) or with (f and Ⅺ) 10 nM insulin. Active glycogen synthase and phosphorylase activity (determined by the active phosphorylase assay) were determined from parallel incubations without radiolabel and are expressed as m-units/mg. Values represent the means Ϯ S.E. for four cultures.
distributed among enzymes that have direct or indirect effects on pathway flux (8) . The flux control coefficient of an enzyme is a measure of the sensitivity of metabolic flux to small changes in enzyme activity or concentration. Heinrich and Rapoport (25) defined the control strength in terms of the fractional change in flux that results from a fractional change in enzyme activity, whereas Kacser and Burns (26) defined the sensitivity coefficient in terms of the fractional change in flux that results from a fractional change in enzyme concentration. If the enzyme rate is proportional to the enzyme concentration, then the two definitions are equivalent. However, when an enzyme is regulated by covalent modification, as in the case of liver phosphorylase (1), then the relevant coefficient for determining the degree of control on pathway flux is expressed in terms of the activity of the enzyme. The control coefficient usually has a value between zero (minimum control) and unity (high control) and is either positive or negative, depending on whether the enzyme stimulates or inhibits pathway flux. Enzymes with control coefficients greater than unity are considered to be rare (23) . In muscle, a high degree of control of glucose utilization lies at or before glucose phosphorylation (9 -11) , and in liver high degree of control lies at glucose phosphorylation (12) (13) (14) . In hepatocytes, glucokinase has a high control coefficient on glycogen synthesis, which is glucose-dependent. This is explained by the unique compartmentation of glucokinase that involves glucose-dependent partitioning of the enzyme between a free active state and an inactive state bound to its regulatory protein (12, 14) . The stimulation of glycogenic flux by an increase in glucokinase activity by either translocation (19) or enzyme overexpression (27) is at least in part explained by the increase in glucose 6-P concentration (11) , the product of the glucokinase-catalyzed reaction, which is a potent activator of glycogen synthase (28) . Glucose 6-phosphatase, which lowers the concentration of glucose 6-P in hepatocytes, has a negative control coefficient on glycogen synthesis (13) . However, in contrast with glucokinase, the control coefficient of glucose 6-phosphatase is much lower than unity and is glucose-independent, (Fig 5) Ϫ2.46 Ϯ 0.63 Ϫ2.36 Ϯ 0.77 Ϫ0.51 Ϯ 0.10 Ϫ0.61 Ϯ 0.20 25 mM glucose (Fig 6) Ϫ2.86 Ϯ 0.47 Ϫ0.53 Ϯ 0.15 25 mM glucose ϩ glucokinase overexpression (Fig 6) Ϫ1 . 6 . Combined effects of overexpression of glucokinase and muscle phosphorylase on glycogen synthesis and glycogen synthase activity. Hepatocytes were either untreated (OE and q) or treated (‚ and E) with the four titers of AdCMV-MGP shown in Table II without (q and E) or with (OE and ‚) AdCMV-GKL. Glycogen synthesis (expressed as nmol/3 h per mg) was determined from 3-h incubations with 25 mM [U- confirming that the high control coefficient of glucokinase and its glucose dependence are best explained by the subcellular compartmentation of glucokinase and its association with its regulatory protein (14) . The recent findings that stimulation of glycogen synthesis by leptin is associated with inactivation of phosphorylase (2) and that impaired glycogen synthesis in hepatocytes from fa/fa rats is associated with elevated phosphorylase activity (7) raised the question of the degree of control of glycogen synthesis by phosphorylase activity. In this study, we demonstrate that phosphorylase has a very high negative flux control coefficient on glycogen synthesis, based on two independent approaches (titration with a specific phosphorylase inhibitor and expression of the muscle isoform of phosphorylase).
Three key findings emerged from the studies with phosphorylase inhibitor CP-91149. First, it caused time-dependent inactivation of phosphorylase a and sequential activation of glycogen synthase. This is analogous to the mechanism proposed by Stalmans et al. (22) for the glucose-induced inactivation of phosphorylase and sequential activation of glycogen synthase. Binding of glucose to phosphorylase a causes a conformational change (R-state to T-state) that renders the enzyme a better substrate for dephosphorylation by protein phosphatase-1. Glucose thus favors the conversion of phosphorylase a to phosphorylase b. Because phosphorylase a is a potent inhibitor of glycogen synthase phosphatase by binding to the C terminus of the liver-specific glycogen-targeting subunit (G L ) of protein phosphatase-1 (29, 30) , the decrease in phosphorylase a alleviates the inhibition of synthase phosphatase. This results in a delayed activation of glycogen synthase relative to the inactivation of phosphorylase, which has been described as the "sequential activation of synthase" (1, 22) . The present results support a model whereby CP-91149 favors the T-conformation of phosphorylase and thereby causes the inactivation of phosphorylase and sequential activation of synthase. Second, the phosphorylase inhibitor markedly increases the sensitivity of glycogen synthesis to glucose (S 0.5 , 19 versus 26 mM) by causing a greater fold stimulation of glycogen synthesis at 5 mM glucose than at 20 mM glucose. This is consistent with the higher activity of phosphorylase a at low glucose and the greater fractional inactivation by the inhibitor at low glucose. The rate of glucose phosphorylation in hepatocytes is a sigmoidal function with respect to [glucose] but with a higher S 0.5 for glucose than can be explained by glucokinase kinetics (20 versus 9 mM) (31) . This higher S 0.5 for glucose phosphorylation in the intact cell is explained by the glucokinase regulatory protein, which functions as a competitive inhibitor with respect to glucose and as a nuclear receptor for the enzyme (32, 33) . Glycogen synthesis has a higher S 0.5 for glucose than glucose phosphorylation in intact cells (33) . The inhibitor studies show that phosphorylase is a major component of the mechanism that accounts for the difference in glucose saturation curves of glycogen synthesis and glucose phosphorylation. Third, the titrations with increasing concentration of inhibitor show a large fractional increase in glycogen synthesis for a corresponding inactivation of phosphorylase, with a control coefficient greater than unity.
We show in this study that muscle phosphorylase expressed using recombinant adenovirus is a powerful tool to alter the catalytic activity of phosphorylase in hepatocytes independently of the cAMP status and/or the phosphorylation state of the cell. In the absence of glucagon, muscle phosphorylase is expressed mainly in the unphosphorylated (b) form. However, it is partially catalytically active at physiological concentrations of AMP and ATP, unlike liver phosphorylase b (16) , and this enables determination of the flux control coefficient of phosphorylase in defined substrate and hormone conditions. By using low titers of adenovirus that result in small fractional changes in phosphorylase activity and a short culture time after treatment with the adenovirus (Ͻ20 h), secondary changes in gene expression are minimized. Two metabolic effects of muscle phosphorylase expression were noted, inactivation of glycogen synthase, which was progressive with enzyme expression, and a decrease in glycogen synthesis, which reached a plateau at low levels of phosphorylase expression. The lack of effect of AdCMV-MGP treatment on ATP, glucose 6-P, glucokinase activity, glycolysis, or conversion of glucose to triacylglycerol indicates that at the viral titers and incubation times used, the effects of muscle phosphorylase expression are confined to glycogen metabolism. The inactivation of synthase and lack of effect on triacylglycerol metabolism contrast with findings on phosphorylase overexpression in muscle cultures (34) . This may represent a tissue difference, or it may be related to the lower levels of phosphorylase overexpression used in the present study.
The inhibition of glycogen synthase by muscle phosphorylase overexpression is of interest because it was not associated with either a change in glucose 6-P, an activator of synthase phosphatase (28) , or an increase in phosphorylase a, a potent allosteric inhibitor of synthase phosphatase (1) . Two types of mechanism can be considered, involving either catalytic activity of phosphorylase or an effect of the protein independent of catalytic activity. Catalytic activity of muscle phosphorylase may cause dissociation of glycogen synthase from glycogen, an allosteric effector of the enzyme (35), or from glycogenin, which is also a substrate for phosphorylase (36) , or it may cause dissociation of a glycogen-targeting subunit of protein phosphatase-1 such as G L or PTG (37) from glycogen. Muscle phosphorylase b may bind to a glycogen-targeting unit and cause inactivation of synthase phosphatase activity either through an allosteric effect (29, 30) or by competitive binding with glycogen synthase (38) . G L has a high-affinity site for phosphorylase a as well as a substrate site, whereas PTG has a single binding site for glycogen synthase and phosphorylase (38) . Inhibition of synthase phosphatase by phosphorylase b has been demonstrated, but with much lower affinity than that for phosphorylase a (39) . The experiments with CP-91149, which counteracted the inhibitory effects of low levels of muscle phosphorylase overexpression on glycogen synthesis and glycogen synthase, suggest that the catalytic activity of phosphorylase accounts for the inhibition of synthase by low levels of phosphorylase expression. However, an additional protein effect independent of catalytic activity at higher levels of muscle phosphorylase expression cannot be ruled out. Two points are of interest with regard to the inhibition of glycogen synthesis by phosphorylase overexpression. First, the high control coefficient is observed at both 10 and 25 mM glucose and is also observed in the presence of insulin. This contrasts with the strong glucose dependence of the control coefficient of glucokinase (12, 13) . Second, unlike the control coefficients of glucokinase or its regulatory protein (positive and negative, respectively), which are sustained over a wide range of protein overexpression (2-3-fold above endogenous activity (13)), inhibition of glycogen synthesis by muscle phosphorylase reaches a plateau (50% inhibition) at low levels of phosphorylase overexpression (Ͻ30% above endogenous activity), with no further inhibition at higher protein expression. If the inhibition of [
14 C]glucose incorporation into glycogen were due to increased degradation of glycogen rather than inhibition of synthesis, then a progressive or a linear response as a function of phosphorylase activity would be expected, as is observed for inactivation of synthase. A more plausible explanation for the sharp inhibition of glycogen synthesis that reaches a plateau at fairly low activities of phosphorylase is that it represents inhibition of synthesis and that there are two compartments of glycogen synthesis, only one of which is sensitive to inhibition by phosphorylase.
The lack of correlation between the rate of glycogen synthesis and the activity of glycogen synthase at high phosphorylase overexpression could be explained by compartmentation of glycogen synthase (40) . The rate of glycogen synthesis in hepatocytes may depend on the fraction of glycogen synthase that is associated with glycogen or the protein primer, glycogenin. An increase in phosphorylase activity may cause dissociation of synthase from glycogenin, which is a substrate for phosphorylase (36) . By analogy with the high flux control coefficient of glucokinase on glycogen synthesis, which is explained by the subcellular compartmentation of glucokinase (12) , the high flux control coefficient of phosphorylase on glycogen synthesis could be due in part to an effect of phosphorylase catalytic activity on the subcellular compartmentation of glycogen synthase. This hypothesis is consistent with both the higher flux control coefficient of phosphorylase on glycogen synthesis relative to the control coefficient on glycogen synthase and the effect of glucokinase overexpression, which lowers the flux control coefficient of phosphorylase on glycogen synthesis but not on synthase. Overexpression of glucokinase increases the hepatocyte glucose 6-P content (27) , and glucose 6-P affects the translocation of glycogen synthase (41) . A difference in subcellular compartmentation of glycogen synthase in cells overexpressing glucokinase could therefore explain the lower control coefficient and could also explain the lower fractional inhibition of glycogen synthesis by phosphorylase overexpression in cells with elevated glucokinase activity.
One of the advantages of metabolic control analysis is that by providing a quantitative estimate for the degree of control exerted by an enzyme, it enables the study of how this control changes in different physiological or pathological states (8) . This study shows that glucokinase overexpression by 60% above endogenous activity lowers the control coefficient of phosphorylase on glycogen synthesis by 50%. This implies that for a small activation of phosphorylase (below that causing saturation of the response), a smaller inhibition of glycogen synthesis would occur in cells with a higher ratio of glucokinase to its regulatory protein. This is of interest from a physiological perspective because the ratio of glucokinase to its regulatory protein decreases during fasting and increases on refeeding (42) . Therefore, it can be inferred that the flux control coefficient of phosphorylase on glycogen synthesis would be greatest at low ratios of glucokinase to regulatory protein, such as those that occur in the fasted to fed transition. Several inhibitors of glycogen phosphorylase described recently (5, 24, 43-46) could be of therapeutic benefit for inhibiting hepatic glycogenolysis in type 2 diabetes. The high control coefficient of phosphorylase on glycogen synthesis suggests that phosphorylase inhibitors would also be highly effective in promoting hepatic glycogen synthesis in the absorptive state and that the overall effect of an inhibitor that causes inactivation of phosphorylase and sequential activation of synthase is to increase the affinity of glycogen synthesis for glucose.
